Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01932450

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Mei changlin (from the registry)
Registry
  • NCT NCT01932450
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01932450. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
Acronym
RAFALE
Condition
Autosomal Dominant Polycystic Kidney Disease
Condition
Hypertension
Intervention (Procedure)
renal sympathetic denervation
Intervention (Drug)
antihypertensive drugs
Lead sponsor
Mei changlin (class: other)

Record details

Record id
cardio:ct-nct01932450
Content hash
a682af10494bd27c167805ed904c701986f05b4f3792177ee79659b471e79e3c